It was a phase III trial that evaluated the efficacy of letrozole +/− lapatinib in 1286 postmenopausal pts with HR+ advanced breast cancer (ABC), with both HER2-positive and HER2-negative disease, stage III or IV, previously untreated in the metastatic setting. The gene discussed is ERBB2; the disease is breast carcinoma.